|
Absence of hypodiploidy and/or chromosome 13 abnormalities (hypo-CA13) confers superior survival in multiple myeloma (MM) patients (pts): Interim analysis of total therapy (TT) II trial
Fassas, A. B. T., Sawyer, J., McCoy, J., Anaissie, E. J., Lee, C. K., Talamo, G., Wendling, C., Zangari, M., Van Rhee, F., Thertulien, R., Tricot, G. J. and Barlogie, B. (2003). Absence of hypodiploidy and/or chromosome 13 abnormalities (hypo-CA13) confers superior survival in multiple myeloma (MM) patients (pts): Interim analysis of total therapy (TT) II trial. In: 45th Annual Meeting of the American Society of Hematology, San Diego CA, United States, (684A-684A). 6-9 December 2003.
|
|
|
|